Vaxcyte
PCVX
75 hedge funds and large institutions have $971M invested in Vaxcyte in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 35 increasing their positions, 16 reducing their positions, and 11 closing their positions.
119% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 16
12% more capital invested
Capital invested by funds: $868M → $971M (+$103M)
1% more funds holding
Funds holding: 74 → 75 (+1)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
1.64% less ownership
Funds ownership: 85.76% → 84.12% (-1.6%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| 1 |
O
OrbiMed
New York
|
+$6.07M |
| 2 |
BlackRock
New York
|
+$3.23M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$2.97M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.01M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$1.68M |
Top Sellers
| 1 |
PA
Perceptive Advisors
New York
|
-$16.8M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$8.23M |
| 3 |
State Street
Boston,
Massachusetts
|
-$5.5M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.46M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$2.32M |
PCVX Hedge Fund Activity: Q2 2021 in Review
75 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q2 2021, worth a combined $971M — up 12% from $868M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new PCVX positions and 11 closed out — a net gain of 1 holder — while 35 added to existing stakes and 16 trimmed.
The largest buyer was OrbiMed, adding an estimated $6.07M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $16.8M sold.
- 75 institutional investors held Vaxcyte (PCVX) as of Q2 2021, up from 74 in Q1 2021.
- Funds reported $971M of Vaxcyte stock for Q2 2021, up 12% quarter-over-quarter.
- 12 funds opened new Vaxcyte positions in Q2 2021 and 11 closed out, a net change of +1 holder.
- The largest Vaxcyte buyer in Q2 2021 was OrbiMed, an estimated $6.07M added.
- The largest Vaxcyte seller in Q2 2021 was Perceptive Advisors, an estimated $16.8M sold.
Based on aggregated 13F filings for Q2 2021.